SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

The Politicization Of The US Patent System

The Washington Post story, How patent reform’s fraught politics have left USPTO still without a boss (July 30), is a vivid account of how patent reform has divided the US economy, preempting a possible replacement for David Kappos who stepped down 18 months ago. The division is even bigger than portrayed. Universities have lined up en masse to oppose reform, while main street businesses that merely use technology argue for reform. Reminiscent of the partisan divide that has paralyzed US politics, this struggle crosses party lines and extends well beyond the usual inter-industry debates. Framed in terms of combating patent trolls through technical legal fixes, there lurks a broader economic concern – to what extent ordinary retailers, bank, restaurants, local banks, motels, realtors, and travel agents should bear the burden of defending against patents as a cost of doing business.


Latest Comments
  • “We want everybody to agree on the science telling... »
  • So this is how we mankind will become extinct? No ... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    Inside Views
    Inside Views: The EU-Thailand FTA: What Fate For Access To Medicines?

    Published on 12 December 2013 @ 6:40 pm

    Disclaimer: the views expressed in this column are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this forum, which remain solely the responsibility of their authors.

    Intellectual Property Watch

    By Tessel Mellema

    Following the public outcry over the EU’s demands for stringent intellectual property rules that would dramatically raise medicines prices in India, you would expect the EU to think twice about making similar demands in future trade agreements, particularly with low- and middle-income countries. Yet, this is precisely what is going on now in the negotiations for a free trade agreement between the EU and Thailand.

    Delegates from both countries are meeting this week in Brussels for the third round of negotiations. Ahead of this round, a delegation of leading activists and academics from Thailand visited Brussels to share their concerns with the European Commission negotiating team and members of the European Parliament.

    Why? Because there is tremendous pressure on Thailand to conclude a trade deal with the EU. The Generalised Scheme of Preferences (GSP), under which Thailand currently benefits from trade preferences with the EU, is to end at the beginning of 2015, and Thailand is being hastened into concluding a trade deal in an unprecedented short time frame. Negotiations are scheduled to finish before the beginning of 2015.

    The question is: Will the EU use these trade negotiations to—once more—put up more monopoly barriers that will sustain the status quo of inequity in health between citizens in high and low/middle income countries?

    Civil society groups in Thailand and Europe have sounded the alarm over these negotiations in the past months. We fear that access to medicines for people living in Thailand will be one of the things traded away. This will seriously jeopardise the current national health coverage system, under which more than 90 per cent of the population receive drugs on the national essential medicines list free of charge.

    And we have good reasons for this fear. A recently leaked draft negotiating text shows that the EU is pressing for stringent intellectual property and investment protection demands that can affect the right to health.

    Thailand has a national health coverage and HIV/AIDS treatment programme in place, guaranteeing almost universal free access to antiretroviral drugs (ARVs) and other drugs on the national essential medicines list to its citizens. It produces generic versions of some essential drugs and has used legal flexibilities to intellectual property rules (TRIPS flexibilities), including compulsory licenses, to sustain its treatment programmes in the past.

    Overreaching intellectual property protection and enforcement restricts and delays legitimate competition from generic manufacturers. It sustains market monopolies, high monopoly prices, and affects access to affordable treatment. This is, however, what the EU is proposing in the leaked draft negotiating text.

    For example, in one chapter, the EU is proposing rules that would expand and lengthen patent monopolies on drugs through data exclusivity and patent term extensions. Patents were intended to be a reward for successful research and development (R&D). But companies are seeking additional rewards for data gathered during the R&D process in the form of data exclusivity provisions that, in effect, prolong their monopoly period. This comes at the expense of access to medicines.

    A prospective impact study done in Thailand, which used a macro economic model to measure the impact of data exclusivity and patent term extension proposals, forecasted that all scenarios (patent extensions of 2, 5 or 10 years and data exclusivity rules of 5 or 10 years) would have a negative impact on the pharmaceutical market. It would lead to increased drug expenditures, reduced access to medicines and a contraction of the domestic pharmaceutical market.

    Another worrying chapter is that on ‘investment protection’. The EU is likely to introduce a provision that protects intellectual property rights held by multinationals, including patents on drugs, as an ‘investment’. Foreign investors will get the right to sue governments for damages if the government’s actions interfere with the enjoyment of their investments.

    Under these investment rules, pharmaceutical companies could sue the government of Thailand, arguing that the government’s measures to promote access to medicines, such as a compulsory license, will negatively affect their monopoly patent rights in Thailand. This may seriously threaten the possibility for the government of Thailand to take measures to reduce the costs of medicines.

    This is not only of concern for low- and middle-income countries; there is currently an ongoing and heated public debate within Europe over the adverse impact on health of similar investment protection proposals in the context of the EU-US free trade agreement (TTIP).

    The EU should learn from the global outcry against strong intellectual property and investment rules in previous trade negotiations. It should not trade away the health of citizens in Thailand just to reach a beneficial trade agreement. The EU must consider the broader context and effects of its intellectual property and investment demands in trade agreements, not only for public health, but also for socioeconomic development.

    Thailand should be allowed the policy space to regulate for the health of its citizens. If not, people in Thailand may, in the future, no longer have access to the medicines they need.


    Tessel Mellema is a policy advisor with Health Action International Europe. She specialises in intellectual property (IP) law with specific expertise on the interplay of IP and EU policies that may have an impact on access to medicines within the EU and abroad. At Health Action International Europe she is responsible for the EU Trade & Access, and Essential Innovation & Access campaigns.

     


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 89.101.71.113